80 related articles for article (PubMed ID: 19887864)
1. The importance of growth factors and steroid hormones in ovarian cancer.
Langdon SP; Faratian D; Harrison DJ
Onkologie; 2009 Nov; 32(11):623-4. PubMed ID: 19887864
[No Abstract] [Full Text] [Related]
2. Multitargeting ovarian epithelial cancer: adding the old to the new.
Garfield DH
J Clin Oncol; 2008 Mar; 26(9):1565-6. PubMed ID: 18349413
[No Abstract] [Full Text] [Related]
3. Key signaling molecules in pituitary tumors.
Tanase CP; Neagu M; Albulescu R
Expert Rev Mol Diagn; 2009 Nov; 9(8):859-77. PubMed ID: 19895231
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of estrogen receptor and progesterone receptor tumor expression in Danish ovarian cancer patients: from the 'MALOVA' ovarian cancer study.
Høgdall EV; Christensen L; Høgdall CK; Blaakaer J; Gayther S; Jacobs IJ; Christensen IJ; Kjaer SK
Oncol Rep; 2007 Nov; 18(5):1051-9. PubMed ID: 17914554
[TBL] [Abstract][Full Text] [Related]
5. Immunophenotype of ovarian cancer as predictor of clinical outcome: evaluation at primary surgery and second-look procedure.
Goff BA; Ries JA; Els LP; Coltrera MD; Gown AM
Gynecol Oncol; 1998 Sep; 70(3):378-85. PubMed ID: 9790791
[TBL] [Abstract][Full Text] [Related]
6. Steroid receptors and Ki-67 reactivity in ovarian cancer and in normal ovary: correlation with DNA flow cytometry, biochemical receptor assay, and patient survival.
Isola J; Kallioniemi OP; Korte JM; Wahlström T; Aine R; Helle M; Helin H
J Pathol; 1990 Dec; 162(4):295-301. PubMed ID: 2290114
[TBL] [Abstract][Full Text] [Related]
7. Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma.
Davidson B; Alejandro E; Flørenes VA; Goderstad JM; Risberg B; Kristensen GB; Trope CG; Kohn EC
Cancer; 2004 May; 100(10):2139-47. PubMed ID: 15139056
[TBL] [Abstract][Full Text] [Related]
8. Correlation between Heterogeneous Expression of Sialyltransferases and MUC16 in Ovarian Tumor Tissues.
Bouanene H; Sahrawi W; Mokni M; Fatma LB; Bouriga A; Limen HB; Khairi H; Ahmed SB; Miled A
Onkologie; 2011; 34(4):165-9. PubMed ID: 21447973
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients.
Smyth JF; Gourley C; Walker G; MacKean MJ; Stevenson A; Williams AR; Nafussi AA; Rye T; Rye R; Stewart M; McCurdy J; Mano M; Reed N; McMahon T; Vasey P; Gabra H; Langdon SP
Clin Cancer Res; 2007 Jun; 13(12):3617-22. PubMed ID: 17575226
[TBL] [Abstract][Full Text] [Related]
10. The oestrogen receptor-negative/progesterone receptor-positive breast tumour: a biological entity or a technical artefact?
Rhodes A; Jasani B
J Clin Pathol; 2009 Jan; 62(1):95-6. PubMed ID: 19103868
[No Abstract] [Full Text] [Related]
11. [A trip through the signaling pathways of melanoma].
Fensterle J
J Dtsch Dermatol Ges; 2006 Mar; 4(3):205-17. PubMed ID: 16626317
[TBL] [Abstract][Full Text] [Related]
12. Vascular endothelial growth factor activating matrix metalloproteinase in ascitic fluid during peritoneal dissemination of ovarian cancer.
Yabushita H; Shimazu M; Noguchi M; Kishida T; Narumiya H; Sawaguchi K; Noguchi M
Oncol Rep; 2003; 10(1):89-95. PubMed ID: 12469150
[TBL] [Abstract][Full Text] [Related]
13. Analysis of potential prognostic factors in 111 patients with ovarian cancer.
Hornung R; Urs E; Serenella E; Edward W; Ursula S; Urs H; Daniel F
Cancer Lett; 2004 Mar; 206(1):97-106. PubMed ID: 15019165
[TBL] [Abstract][Full Text] [Related]
14. Glucocorticoids inhibit cell death in ovarian cancer and up-regulate caspase inhibitor cIAP2.
Runnebaum IB; Brüning A
Clin Cancer Res; 2005 Sep; 11(17):6325-32. PubMed ID: 16144937
[TBL] [Abstract][Full Text] [Related]
15. Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities.
Massarweh S; Schiff R
Clin Cancer Res; 2007 Apr; 13(7):1950-4. PubMed ID: 17404074
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical analysis of a primary ovarian leiomyosarcoma. Case report.
Mayerhofer K; Lozanov P; Bodner K; Bodner-Adler B; Mayerhofer-Gallenbacher N; Hudelist G; Czerwenka K
Anticancer Res; 2003; 23(4):3433-6. PubMed ID: 12926085
[TBL] [Abstract][Full Text] [Related]
17. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer.
Jones MB; Krutzsch H; Shu H; Zhao Y; Liotta LA; Kohn EC; Petricoin EF
Proteomics; 2002 Jan; 2(1):76-84. PubMed ID: 11788994
[TBL] [Abstract][Full Text] [Related]
18. The orphan nuclear receptors, estrogen receptor-related receptors: their role as new biomarkers in gynecological cancer.
Sun P; Wei L; Denkert C; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1699-706. PubMed ID: 16617564
[TBL] [Abstract][Full Text] [Related]
19. WT1, estrogen receptor, and progesterone receptor as markers for breast or ovarian primary sites in metastatic adenocarcinoma to body fluids.
Lee BH; Hecht JL; Pinkus JL; Pinkus GS
Am J Clin Pathol; 2002 May; 117(5):745-50. PubMed ID: 12090423
[TBL] [Abstract][Full Text] [Related]
20. Oestrogen receptor beta in breast cancer: good, bad or still too early to tell?
Speirs V
J Pathol; 2002 Jun; 197(2):143-7. PubMed ID: 12015736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
